Investigators teased out imaging signals and underlying biology that can differentiate the subset of brain cancers for which tumor DNA can be detected in blood.
The company has been collecting data on broader applicability of its electric field chip technology for potential use in DNA, RNA, exosome, and protein applications.
Although the study was small, the investigators believe it provides proof of principle for the usefulness of cell-free DNA to prognose and monitor glioblastomas.
In PNAS this week: transcriptomic and epigenomic sequence differences in glioblastoma models, approach to analyze small amounts of extracellular RNA, and more.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
